Adrenocortical carcinoma

Netherlands Journal of Medicine

Volumn 65, Issue 2, 2007, Pages 55-59

  van Ditzhuijsen, C I M ^a   van de Weijer, R ^a   Haak, H R ^a  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

Author keywords

Adrenocortical carcinoma; Therapy; Treatment

Indexed keywords

CISPLATIN; CORTICOTROPIN RECEPTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; MITOTANE; PROTEIN P53; PROTEIN P57; STREPTOZOCIN; VINCRISTINE;

ABDOMINAL MASS; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ANOREXIA; ATAXIA; BECKWITH WIEDEMANN SYNDROME; BLEEDING TIME; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; ENDOCRINE DISEASE; ENDOCRINOLOGY; FAMILIAL CANCER; GASTROINTESTINAL SYMPTOM; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HUMAN; INSOMNIA; MEDICAL EXPERT; MEDICAL SPECIALIST; NAUSEA; NETHERLANDS; NEUROLOGIC DISEASE; ONCOLOGY; PATHOLOGIST; PATIENT CARE; PROFESSIONAL KNOWLEDGE; PROGNOSIS; RARE DISEASE; REVIEW; SIDE EFFECT; STEROID BLOOD LEVEL; SYMPTOMATOLOGY; TREMOR; VOMITING;

ACADEMIC MEDICAL CENTERS; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS; DOXORUBICIN; ETOPOSIDE; HUMANS; INTERNATIONALITY; MITOTANE; NETHERLANDS; STREPTOZOCIN;

EID: 33847421876     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Allolio B, Hahner S, Weisman D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol 2004;60:273-87.
2. van der Leeuw PJ. Case report; adrenocortical carcinoma. Neth J Med 1964;86:1143-8.
3. Roelofs EJM, de Mulder PHM, Hermus ARMM. Treatment of adrenocortical carcinoma. Neth J Med 1993;137:2576-9.
4. Schreinemakers JMJ, van Dam PS, Seldenrijk CA, Biesma DH, Borel Rinkes IHM. Adrenocortical carcinoma, a tumor with clinical significance. Neth J Med 2004;148:2109-13.
5. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 2003;169:5-11.
6. Samaan NA, Hickey RC. Adrenocortical Carcinoma. Sem Oncol 1987;14:292-6.
7. Alliolio B, Fassnacht M. Clinical review: Adrenocortical Carcinoma. J Clin Endocrinol Metab 2006;91:2027-37.
8. Mcfarlane DA. Cancer of the adrenal cortex. Ann R Coll Surg 1958;23:155-86.
9. Vassilopoulou-Sellin R, Schultz PN Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 2001;92:1113-21.
10. Holleman F, Endert E, Prummel MF, van Vessem-Timmermans M, Wiersinga WM, Fliers E. Evaluation of Endocrine Tests. B: screening for cortisolism. Neth J Med 2005;63:348-53.
11. Derksen J, Nagesser SK, Meinders AE, Haak HR, van de Velde CJH. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994;331:968-73.
12. Van Slooten H, Schaberg A, Smeenk D, Molenaar AJ. Morphological characteristics of benign and malignant adrenocortical tumors. Cancer 1985;55:766-73.
13. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984;8:163-9.
14. Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proye C. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortocal tumors. Am J Surg Pathol 2002;26:1612-9.
15. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002;87:5367-84.
16. Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 2001;86:4970-73.
17. Henry I, Jeanpierre M, Couillin P, Barichard F, Serre JL, Journel H, et al. Molecular definition of the 11p15.5 region involved in Beckwith-Wiedemann syndrome and probably in predisposition to adrenocortical carcinoma. Hum Genet 1989;81:273-7.
18. Haak HR, Hermans J, van de Velde CJH, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results of a consecutive series of 96 patients. Br J Cancer 1994;69:947-51.
19. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o.p'DDD) levels on the treatment of patients with adrenocortical conserved carcinoma. Cancer 2001;92:1385-92.
20. Haak HR, Caekebeke-Peerlinck KM, van Seters AP, Briet E. Prolonged bleeding time due to mitotane therapy. Eur J Cancer 1991;27:638-41.
21. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide, doxorubicin and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 1998;83:2194-200.
22. Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long term survival in its adjuvant use. Ann Oncol 2000;11:1281-7.
23. Collaborative group for Adrenocortical Carcinoma Therapy. Clinical Study Protocol. FIRM-ACT, April 2004.